T P Alekseeva

City Clinical Hospital named after S.S. Yudin, Moscow, Russia.

2 publications 2010 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does T P Alekseeva research?

T P Alekseeva studies thrombolytic therapy, specifically the use of a medication called Revelise (alteplase) in treating ischemic strokes. Ischemic strokes occur when there is a blockage in the blood vessels supplying the brain, cutting off blood flow. Alekseeva's research investigates how well this medication performs in real-world scenarios, particularly focusing on different patient populations including older adults and those with existing health issues.

Key findings

  • In the study involving 2,202 patients, 49.9% had good outcomes at discharge after receiving Revelise for their ischemic stroke.
  • The percentage of patients with favorable outcomes increased to 66.4% after 90 days post-treatment.
  • The results indicate that Revelise significantly reduces stroke-related disabilities in patients, regardless of age and comorbidities.

Frequently asked questions

Does Dr. Alekseeva study ischemic strokes?
Yes, Dr. Alekseeva researches treatments for ischemic strokes, focusing on the use of Revelise (alteplase).
What treatments has Dr. Alekseeva researched?
Dr. Alekseeva has specifically researched thrombolytic therapy using Revelise for managing ischemic stroke.
Is Dr. Alekseeva's work relevant to older stroke patients?
Yes, Dr. Alekseeva's research demonstrates that Revelise is effective in older patients and those with additional health issues.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Wound healing potential of chitosan and its N-sulfosuccinoyl derivatives].

2010

Izvestiia Akademii nauk. Seriia biologicheskaia

Alekseeva TP, Rakhmetova AA, Bogoslovskaia OA, Ol'khovskaia IP, Levov AN +4 more

Plain English
This study looked at how well chitosan and its modified versions help heal wounds by testing them on skin wounds in a lab setting. The researchers found that a specific modified chitosan, when included in a gel at a concentration of 0.05%, significantly sped up the healing process, reducing the time for wounds to heal by 2 to 3 times compared to a control group. This is important because faster wound healing can lead to better care and recovery for patients with injuries. Who this helps: Patients with wounds or skin injuries.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.